KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Assets (2016 - 2025)

Historic Current Assets for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $281.4 million.

  • Nektar Therapeutics' Current Assets fell 178.86% to $281.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.4 million, marking a year-over-year decrease of 178.86%. This contributed to the annual value of $261.3 million for FY2024, which is 2098.84% down from last year.
  • As of Q3 2025, Nektar Therapeutics' Current Assets stood at $281.4 million, which was down 178.86% from $186.6 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Current Assets registered a high of $1.1 billion during Q1 2021, and its lowest value of $186.6 million during Q2 2025.
  • Its 5-year average for Current Assets is $526.5 million, with a median of $441.1 million in 2023.
  • Per our database at Business Quant, Nektar Therapeutics' Current Assets crashed by 3942.85% in 2023 and then plummeted by 178.86% in 2025.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Current Assets stood at $795.6 million in 2021, then crashed by 31.37% to $546.0 million in 2022, then tumbled by 39.43% to $330.7 million in 2023, then fell by 20.99% to $261.3 million in 2024, then grew by 7.68% to $281.4 million in 2025.
  • Its Current Assets was $281.4 million in Q3 2025, compared to $186.6 million in Q2 2025 and $229.9 million in Q1 2025.